New immunotherapy cocktail targets tough colon cancer

NCT ID NCT07253896

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding an immunotherapy drug (AK104) to standard chemotherapy and a targeted therapy (cetuximab or bevacizumab) can shrink tumors in people with a specific type of advanced colorectal cancer (MSS type) that has already been treated once. The study will enroll 40 adults aged 18-75. The main goal is to see how many patients have a significant reduction in tumor size that lasts at least 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK104 (a type of immunotherapy) combined with chemotherapy (FOLFIRI) and either cetuximab or bevacizumab
What this could lead to: If successful, this could offer a new second-line treatment option for people with a common type of advanced colorectal cancer that hasn't responded to initial therapy.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply broadly. The combination of drugs may cause significant side effects, and the treatment may not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SAFETY

Contacts and locations

Locations

the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310000, China
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITING

Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.